Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies

Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies

Rituximab (R) is increasingly incorporated in reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in patients with B-cell malignancies, not only to improve disease control, but also to prevent graft-versus-host disease (GVHD). There are no random...

Full description

Bibliographic Details
Main Authors: Agnieszka Tomaszewska, Madan Jagasia, Eric Beohou, Steffie van der Werf, Didier Blaise, Edward Kanfer, Noel Milpied, Péter Reményi, Fabio Ciceri, Jean H. Bourhis, Patrice Chevallier, Carlos Solano, Gerard Socié, Benedetto Bruno, Alessandro Rambaldi, Luca Castagna, Nicolaus Kröger, Paolo Corradini, Boris Afanasyev, Marco Ladetto, Dietger Niederwieser, Christof Scheid, Henrik Sengeloev, Frank Kroschinsky, Ibrahim Yakoub-Agha, Helene Schoemans, Christian Koenecke, Olaf Penack, Zinaida Perić, Hildegard Greinix, Rafael F. Duarte, Grzegorz W. Basak
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Immunology
Subjects:
transplantation
B-cell malignancy
conditioning
rituximab
non-relapse mortality after hematopoietic cell transplantation
graft-versus-host disease
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.613954/full

Similar Items

Similar Items